{
  "abstract": "Introduction and Objectives Treatment goals for severe asthma include disease remission. In the phase 3 NAVIGATOR study in severe uncontrolled asthma ( NCT03347279), 28.5% of tezepelumab recipients achieved on-treatment clinical remission over weeks 0–52 (placebo, 21.9%). In the phase 3b WAYFINDER study in OCS-dependent severe asthma (NCT05274815), OCS discontinuation without loss of asthma control was achieved by 32.2% of tezepelumab recipients at week 28 and 50.3% at week 52. This post hoc analysis assessed the proportion of WAYFINDER participants who achieved on-treatment clinical remission at weeks 28 and 52.Methods WAYFINDER was an open-label, single-arm, OCS-sparing study in adults with severe asthma on maintenance OCS (mOCS). Patients received tezepelumab 210 mg subcutaneously every 4 weeks for 52 weeks. Clinical remission was defined as an Asthma Control Questionnaire-6 score <1.5, a post-bronchodilator forced expiratory volume in 1 second ≥95% of baseline and no use of mOCS at the end of the time period and no exacerbations over the time period.Results Overall, 298 patients received tezepelumab. The proportion of patients achieving all clinical remission criteria was 12.4% (28/226) at week 28 and 24.3% (51/210) at week 52 ( figure 1).Abstract P202 Figure 1Proportion of WAYFINDER participants who achieved on-treatment clinical remission at week 28 and week 52Conclusions About a quarter of OCS-dependent patients with severe asthma achieved clinical remission by 52 weeks of tezepelumab treatment.",
  "authors": [
    {
      "affiliations": [
        "Guys Severe Asthma Centre, Guys and St Thomas NHS Foundation Trust, London, UK",
        "School of Immunology and Microbial Sciences, Kings College London, London, UK"
      ],
      "name": "DJ Jackson"
    },
    {
      "affiliations": [
        "Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, USA"
      ],
      "name": "NL Lugogo"
    },
    {
      "affiliations": [
        "Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Cambridge, UK",
        "National Institute for Health and Care Research Cambridge Biomedical Research Centre, Addenbrooke’s Hospital, Cambridge, UK"
      ],
      "name": "M Gurnell"
    },
    {
      "affiliations": [
        "Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queens University Belfast, Belfast, UK"
      ],
      "name": "LG Heaney"
    },
    {
      "affiliations": [
        "IKF Pneumologie Mainz, Mainz, Germany",
        "Thoraxklinik Heidelberg, Heidelberg, Germany"
      ],
      "name": "S Korn"
    },
    {
      "affiliations": [
        "Department of Respiratory Medicine, Ghent University Hospital, Gent, Belgium"
      ],
      "name": "G Brusselle"
    },
    {
      "affiliations": [
        "Department of Respiratory Diseases, Aix-Marseille University, Marseille, France"
      ],
      "name": "P Chanez"
    },
    {
      "affiliations": [
        "Diagnostic and Treatment Department, Hospital de Rehabilitación Respiratoria M. Ferrer and IDIM CR, Buenos Aires, Argentina"
      ],
      "name": "R del Olmo"
    },
    {
      "affiliations": [
        "Global Medical Affairs, Amgen, Thousand Oaks, USA"
      ],
      "name": "J-P Llanos"
    },
    {
      "affiliations": [
        "Biometrics, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Barcelona, Spain"
      ],
      "name": "J Moreno Sepena"
    },
    {
      "affiliations": [
        "Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Gothenburg, Sweden"
      ],
      "name": "C Marchese"
    },
    {
      "affiliations": [
        "Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Gaithersburg, USA"
      ],
      "name": "B Cook"
    },
    {
      "affiliations": [
        "Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, Cambridge, UK",
        "Institute for Lung Health, National Institute for Health and Care Research, Leicester, UK"
      ],
      "name": "N Martin"
    },
    {
      "affiliations": [
        "Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, Cambridge, UK"
      ],
      "name": "S Chandarana"
    },
    {
      "affiliations": [
        "Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Gaithersburg, USA"
      ],
      "name": "A Parulekar"
    }
  ],
  "title": "P202 On-treatment clinical remission with tezepelumab in OCS-dependent patients with severe asthma in WAYFINDER",
  "uid": "c9b9b33b-b6fc-54f3-8245-e1caef7a9725"
}